The world has been faced with the coronavirus disease 2019 (COVID-19) pandemic.
Several antiviral medications have been granted emergency use authorization for treatment …

To the Editors, We read with interest the article by Axelrad et al, 1 which reported that
patients with inflammatory bowel disease (IBD) are not at increased risk of COVID-19 and …

Background While there are multiple safe and effective agents for COVID-19 treatment, their
impact in inflammatory bowel disease (IBD) remains uncertain. Aims Our objective was to …

Objective Our aim was to explore the risk of infection with all classes of inflammatory bowel
disease (IBD) medications and the impact of these medications on the disease course in a …

(SECURE-IBD) database, an international, collaborative database created to monitor COVID-
19 outcomes in patients with inflammatory bowel disease (IBD), has previously reported that …

Background Patients with inflammatory bowel disease (IBD) often require the use of
immunosuppressant medications that increase infection risk, leading to concerns over the …

EDITORS, We read with interest the study by Taxonera et al, describing clinical
characteristics and mortality associated with COVID-19 in a Spanish inflammatory bowel …

Background Older age and comorbidities are the main risk factors for adverse COVID‐19
outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications …

Background Our understanding of coronavirus disease 2019 (COVID-19) and its
implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We …

Objectives COVID-19 has evolved into a global health crisis, variably affecting the
management of patients with chronic illnesses. Patients with inflammatory bowel disease …